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ABSTRACT
Objective: To evaluate the cost-effectiveness of ertapenem versus
piperacillin/tazobactam in the treatment of community-acquired compli-
cated intraabdominal infections accounting for development of antibiotic
resistance in the Dutch setting.
Methods: A decision tree was developed to estimate cost-effectiveness of
ertapenem versus piperacillin/tazobactam at different time points after
introduction of treatment. Development of resistance was incorporated
using a compartment model. Resistance was a function of the eradication
rate of pathogens and antibiotic prescription. Model outcomes included
quality-adjusted life years (QALYs), direct costs and cost per QALY saved.
Microbiological eradication rate, clinical success, and costs were derived
from literature. The analyses included pathogens with intrinsic or acquired
resistance.
Results: The model suggested overall savings of €355 (95% uncertainty
interval €480; €1205) per patient when abdominal infections are treated
with ertapenem instead of piperacillin/tazobactam. Probabilistic sensitivity
analysis found a 94% probability of the incremental cost per QALY saved
being within the generally accepted threshold for cost-effectiveness
(€20,000). After 5 years, it is expected that antibiotic resistance with
piperacillin/tazobactam has increased with a greater rate compared to
ertapenem, and cost-savings with ertapenem are expected to increase to
€672 (€-232; €1617). Ertapenem will, in addition, result in greater success
rates and in QALY savings (0.17; 0.07–0.30). Alternative scenarios, with
lower levels of initial resistance conﬁrm the cost savings with ertapenem.
Conclusion: Given the underlying assumptions and data used, this evalu-
ation demonstrated that ertapenem is a cost saving and possibly an eco-
nomically dominant therapy over piperacillin/tazobactam for the treatment
of community-acquired intraabdominal infections in The Netherlands.
Keywords: antimicrobial resistance, compartment model, cost-
effectiveness, intraabdominal infections.
Introduction
Complicated intraabdominal infections (IAI) are commonly
observed in surgical practice and can contribute to unfavorable
outcomes (e.g., morbidity and mortality) [1]. IAIs are deﬁned as
the presence of a purulent exudate in the abdominal cavity
caused by, for example, abdominal surgery, trauma, or organ
perforations [2]. Complicated IAI extend beyond the hollow
viscus of origin into the peritoneal space and are associated with
abscess forming or with peritonitis [3]. It is estimated that
approximately 80% of all IAI are community acquired; i.e.,
infections contracted outside of a hospital setting [1]. The infect-
ing ﬂora consist of aerobic, facultative, and anaerobic gram-
negative bacilli, various streptococci and enterococci, and an
excess of gram-positive anaerobes [4–6].
IAIs are typically managed using surgical intervention in con-
junction with antibiotic therapy [7,8]. Piperacillin/tazobactam
and ertapenem showed equivalence in a randomized controlled
trial (RCT) and are commonly used in the treatment of IAIs [9].
Piperacillin is an extended spectrum beta-lactam antibiotic,
together with the beta-lactamase inhibitor tazobactam. It has
activity against many gram-positive, gram-negative pathogens,
and anaerobes. Ertapenem is a novel Group 1 carbapenem that
offers once-a-daymonotherapy and its activity includes themajor-
ity of bacterial pathogens causing most routine community-
acquired infections, including enterobacteriaceae and anaerobes.
The problem with antibiotic therapy is the causal relation
between antibiotic use and the development of antimicrobial
resistance (AMR) [10–13]. With each beneﬁcial application of
these treatments there is the increased likelihood that any anti-
biotic will be less effective for repeated use in the future both for
patients who have been treated with the particular antibiotic
before and for new patients as well. AMR may lead to treatment
failure in the management of IAI when the antibiotic agent to
which the causative agents are resistant to, is used [14]. Entero-
bacteriaceae (e.g., Escherichia coli) are major pathogens in IAI
[1,9]. Over the last decade, resistance to beta-lactams among
these organisms mostly because of extended spectrum beta-
lactamases (ESBL) production has become common both in the
hospitals, and more recently also in the community. These organ-
isms often fail treatment with various beta-lactam agents,
whereas carbapenems, such as ertapenem, retain activity against
ESBL-producing organisms [15,16]. In the Dutch population the
overall prevalence of conﬁrmed ESBL producers close to 6% can
be considered signiﬁcant [17]. More than 40% of all isolates
were identiﬁed as E. coli. The study for monitoring antimicrobial
resistance trends (SMART)—an ongoing global antimicrobial
surveillance program focused on clinical isolates from IAI—
indicates that in Europe about 4% of E. coli is ESBL producing
in community-acquired IAI and 8% in hospital acquired infec-
tions. In Europe the sensitivity of E. coli to piperacillin/
tazobactam is about 95% whereas ertapenem shows sensitivity
close to 100% [18]. DiNubile et al. showed that ertapenem is
ideal for the treatment of moderate to severe polymicrobial infec-
tions where ESBL producers are likely and shows minimal risk
for development of AMR [19]. It is equally important to empha-
size the relevance of anaerobes. In the trial comparing ertapenem
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with piperacillin/tazobactam, more than 30% of the pathogens
were Bacteroides Fragilis and more than 70% other Bacteroides
spp [9].
Complicated IAI are associated with increased hospital
resource consumption and costs [20]. In addition, the evolvement
of selective bacteria has a negative impact on the ﬁnancial
burden. Signiﬁcant cost-drivers related to AMR include cost
related to treatment failure which leads to increased length of
hospital stay, need for excess surgical procedures, other medical
resource consumption, and optionally productivity loss, among
others [21]. A mathematical model provides a valuable frame-
work to link the (epidemiological/biological) dynamics of resis-
tance with economic end points. With such a model the (future)
resistance as well as the economic consequences can be estimated
given certain treatment strategies [21]. Models for AMR have
primarily been developed for nosocomial infections. The key
assumption is that bacteria are transmitted between patients in
hospitals via direct contact between patients, via human vectors,
or through contamination of the environment [22]. Although the
epidemiology of antibiotic treatment and resistance in the hospi-
tal setting is different than in the community, several studies have
also found a positive association between antibiotic use and
antibiotic resistance in the community [22,23]. Furthermore, a
study by Bruinsma et al. among healthy individuals in popula-
tions showed that living in an environment with resistant bacte-
ria is a real risk for acquiring such bacteria, and more important,
the closer the contact the larger the risk [23]. These results
indicate that next to antibiotic prescription, population density is
a factor inﬂuencing the prevalence of AMR. Hence, it can be
argued that mathematical transmission models, as used for noso-
comial infections are also applicable to model community-
acquired infections [24].
Given the economic burden of IAI and AMR, therapeutic
decisions should be based on an evaluation of costs and beneﬁts
of available alternatives [25]. Hence, a cost-effectiveness evalu-
ation, by which the value for money of antimicrobials can be
assessed, is warranted. This study describes the cost-effectiveness
analysis of ertapenem relative to piperacillin/tazobactam for the
treatment of community-acquired complicated IAI for The Neth-
erlands from a limited societal perspective (i.e., only direct
costs). Furthermore, we illustrate how AMR can be taken into
account and how this changes over time, thereby inﬂuencing
cost-effectiveness.
Methods
Model Structure
Two integrated models were developed: 1) A Susceptible-
Infected-Susceptible (SIS) model for the development of AMR
(i.e., reduced sensitivity/effectiveness over time) with ertapenem
and piperacillin/tazobactam in community-acquired IAI [21];
and 2) a decision tree to evaluate the cost-effectiveness of ertap-
enem relative to piperacillin/tazobactam for the treatment of
these infections given the level of AMR obtained from the SIS
model.
Development of antibiotic resistance: SIS-model. The SIS model
is a type of mathematical model consisting of compartments and
reﬂects the dynamic changes in the uninfected population and
those infected with sensitive and resistant strains. Figure 1 pre-
sents the used SIS compartment model for AMR over time for
one antibiotic. The model makes speciﬁc assumptions about the
transmission of antibiotic-sensitive and resistant bacteria among
hosts and the course of the infection. More speciﬁc, AMR devel-
ops as a function of pathogen virulence, infected fraction with a
susceptible strain and a resistant strain, rates of recovery, and
prescription.
Three compartments can be differentiated whose sizes change
over time: uninfected or susceptible hosts (S); hosts infected with
a sensitive strain (Iw) and hosts infected with a resistant strain of
bacteria (Ir). We assume there is a constant population size; in
other words all the people in the population are the same people
from period to period (Eq. 1)
S I Iw r+ + = 1 (1)
Uninfected hosts can become infected with a sensitive or resistant
strain. As indicated by Bruinsma et al. transmission of strains is
a function of population density [23]. The rate of transmission to
uninfected hosts is determined by the density of uninfected and
infected hosts as well as a transmission rate parameter (b)
according to bS(Iw + Ir). The greater the population density is, the
greater the transmission rate parameter. [Please note that this
construct involves multiplying two complementary fractions,
whose product is always greatest when both S and Iw + Ir involve
middle values, for example 0.5 ¥ 0.5 = 0.25, rather than when
extreme values are assumed (0.9 ¥ 0.1 = 0.09)]. The spontaneous
rate of clearance of bacteria from infected hosts can be different
for sensitive and resistant strains, reﬂected with rw and rr. We
assumed that antibiotic treatment accelerates the clearance of
sensitive strains with rate h. The reciprocals of the clearance rates
represent the duration of infection, and therefore the period of
time in which hosts transmit the bacteria. The change in the
density of uninfected and infected hosts is reﬂected with the
arrows in Figure 1. Given the greater clearance rate of sensitive
strains under antibiotic treatment than for resistant strains, the
fraction of hosts with resistant strains will increase over time
relative to the fraction of hosts with sensitive strains, thereby
resulting in an increased AMR over time.
The changes in the transmission rates as a function of the
fraction (i.e., size of compartment) of hosts uninfected and
infected over time as illustrated in Figure 1 can be described by
the following differential equations:
dS
dt
S I I r I r I fI h rw r w w r r w w= − +( ) + + + −( )β (2)
dI
dt
SI r I fI h rw w w w w w= − − −( )β (3)
dI
dt
SI r Ir r r r= −β (4)
For the current model we have assumed that the spontaneous
rate of clearance for sensitive strains is the same as for resistant
strains.
Δr r rr w= − = 0 (5)
The sensitivity of strains to the antibiotic can be expressed with
w according to:
w
I
I I
w
w r
=
+
(6)
By combining the equations 3, 4, 5, and 6 the changes in sensi-
tivity (i.e., 1-resistance) over time can be extracted according to
Eq. 7 as shown by Laxminarayan and Brown [21]
dw
dt
f h r w w= −( ) −( )1 (7)
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The output of the SIS model we are interested in is the sensi-
tivity of bacteria to the antibiotic by month as a function of
the antibiotic prescription distribution (f, this can be called the
treatment strategy), initial resistance (1 - wt=0), spontaneous
rate of clearance (r), and rate of clearance under antibiotic
treatment (h). The larger the proportion of patients that get a
certain antibiotic prescribed, the more rapid resistance will
develop. Note again that this construct involves multiplying
two complementary fractions (w and w-1) and suggests that the
rate of increase in resistance is likely to be most pronounced
when the initial resistance is neither too low nor too high.
The factors r and h remain constant over time and are the same
for both antibiotics (please note from Eq. 7 that the fraction of
hosts infected as well as the transmission rate is not of rel-
evance). The sensitivity over time translates into a correspond-
ing efﬁcacy according to:
p
w
w
psuccess
t
successt =
0
0 (8)
where
psuccess0 is fraction of infected patients that are successfully treated
according to clinical criteria with antibiotic 1 at t = 0 (initial
effectiveness) psuccesst is fraction of infected patients that are suc-
cessfully treated according to clinical criteria with antibiotic 1 at
month t
Decision tree to evaluate cost-effectiveness. The decision tree in
Figure 2 describes the treatment pathway and outcomes relevant
to treatment of IAI. Both ertapenem and piperacillin/tazobactam
can result in a successful outcome with a certain probability. A
clinical success was deﬁned as resolution of the infection, with no
further antibiotic therapy necessary [9]. The clinical success is
related to the sensitivity of the strains to the antibiotic that can
vary by month as a result of development of AMR. In case of a
clinical failure, a second antibiotic will be prescribed which again
has a certain probability of success. If this second antibiotic
treatment fails, the outcome can be either fatal or there will
be sequelae as a result of the bacterial infection. It is assumed
that all events after the prescription of the antibiotic of choice
occur within 1 month. Output variables of the decision tree are:
drug acquisition costs (discounted); cost of other resource con-
sumption [i.e., length of stay, surgery, and outpatient visits]
(discounted); total cost (discounted); mortality and (quality
adjusted) life years lost (discounted); incremental costs; effective-
ness; QALYs saved; and incremental cost-utility ratios. These
output estimates will vary over time as a function of developing
resistance for both ertapenem and piperacillin/tazobactam.
Input Data
Dynamics of antimicrobial resistance. Input data used for the
SIS model includes information on the rate of eradication in
presence of antibiotic treatment (h), the spontaneous clearance
rate (r), and the initial resistance of bacteria (1 - wt=0) to
ertapenem and piperacillin/tazobactam (see Table 1).
)( rw IIS +β
)( ww rhfI −
S
Iw
sensitiveww
Ir
rr Ir
Susceptible Infected
Ir
resistant
Short explanation of compartment model:
•Susceptible hosts (S=1-Iw-Ir) free of strains become infected. 
•The rate of transmission is determined by the fraction of hosts infected and a transmission 
rate parameter ( ) according to S(Iw+Ir)
•Infected hosts can be infected with either a sensitive strain (Iw) or with a resistant strain of 
bacteria (Ir). 
•Clearance of a sensitive or resistant strain without antibiotic treatment is determined by a
spontaneous clearance rate (rw and rr ) 
•Clearance with a specific antibiotic is determined by the rate of clearance under antibiotic 
treatment (h) and fraction (f) treated. 
•h is greater than rw and rr
•Susceptibility of strains to antibiotic is defined as w = Iw/(Iw+ Ir)
•Given the greater clearance rate sensitive strains under antibiotic treatment than for 
resistant strains, the fraction of hosts with resistant strains will increase over time relative to 
the fraction of hosts with sensitive strains. Hence sensitivity (w) of strains will decrease over 
time (i.e. AMR will increase).
•w is used to calculate reduction in clinical efficacy over time (as used in decision tree) 
according to:
0
0
=
=
=
t
t
t
t
successclinicalsuccessclinical p
w
w
p Figure 1 SIS-model for development of antimi-
crobial resistance (Adapted from Laxminarayan
and Brown [21].
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The daily clearance rate with ﬁrst line antibiotic treatment
(h) was calculated as 0.137, based on the average duration of
colonization of 7.3 days with ertapenem and piperacillin/
tazobactam [9]. This corresponds to a probability of 0.984 that
the bacteria are eradicated at the end of the month. The spon-
taneous daily clearance rate (r) was 0.103 under the assump-
tion that the duration of colonization under treatment was
75% of the duration without treatment, i.e., about 10 days.
(Furthermore, after 10 days without success, a second line
antibiotic was assumed to be given.) This corresponded to a
* Probability of Clinical Success is reduced over time as a function of reduced susceptibility of strains to antibiotic 
over time as calculated with compartment model. (See Fig. 1)   
Clinical Success
Success 2nd line
Sequelae 2nd line
Death
Failure 2nd line
2nd line AntibioticClinical Failure
Ertapenem
Piperacillin/ tazobactam
*
Figure 2 Decision tree model for treatment of complicated abdominal infections.
Table 1 Input resistance, clearance, efﬁcacy, costs and utility data for SIS model and decision tree (point estimates and uncertainty interval used for
analysis) of intraabdominal infections in The Netherlands
Ertapenem-arm Piperacillin/tazobactam-arm Source
Susceptible-infected-susceptible
model parameters*
Daily clearance rate with antibiotic
treatment (h)
0.137 0.137 Solomkin et al. [9]
Spontaneous daily clearance rate (r) 0.103 0.103 Assumption (see text for details)
Initial resistance (1 - w) 0.064 (base-case scenario)
0.003 (alternative scenario)
0.106 (base-case scenario)
0.022 (alternative scenario)
Base-case scenario calculated based
on Solomkin et al. [9] (see text for
details);
Alternative scenario based on the
Study for Monitoring Antimicrobial
Resistance Trends program [18]
Decision tree parameters
Initial efﬁcacy (t = 0) (clinical
response)
0.867 (0.823; 0.911) 0.812 (0.760; 0.864) Solomkin et al. [9]
Second line antibiotic efﬁcacy
(imipenam/cilastatin; after clinical
failure)
0.827 (0.744; 0.910)† 0.827 (0.744; 0.910)† Dietrich et al. [26]
Mortality given failure of second-line
antibiotic
0.289 (0.215; 0.363) 0.289 (0.215; 0.363) Dietrich et al. [26]
Discounted Life Expectancy (in
years) with successful outcome
or sequelae
27.5 27.5 Life expectancy of 35 years at age 45
(CBS statline)
Cost of ﬁrst line antibiotic
treatment
7.6 (7.2; 8.0) days
€381.22
(€360.52; €401.92)
7.8 (7.4; 8.2) days
€475.96
(€450.13; €501.78)
Treatment duration based on Solomkin
et al. [9].
Unit cost: medicijnkosten.nl
Cost of second-line antibiotic
treatment (imipenem/cilastatin)
8.0 (7.0; 14.0) days
€931.04
(€814.66; €1629.32)
8.0 (7.0; 14.0) days
€931.04
(€814.66; €1629.32)
Krobot et al. [27]; medicijnkosten.nl
Total cost of length of stay with
clinical success ﬁrst-line
antibiotic
12.0 (10.0; 14.0) days
€4512
(€3760; €5264)
12.0 (10.0; 14.0) days
€4512
(€3760; €5264)
Davey et al. [28]; kostenhandleiding CVZ
Total cost of length of stay without
clinical success ﬁrst-line antibiotic
22.0 (18.0; 26.0) days
€8272
(€6768; €9777)
22.0 (18.0; 26.0) days
€8272
(€6768; €9777)
Davey et al. [28]; kostenhandleiding CVZ
Cost of surgery (all patients) €3908
(€2617; €9917)
€3908
(€2617; €9917)
DBC
Cost related to outpatient visits 2 (0; 2) visits
€131.96
(€0; €131.96)
2 (0; 2) visits
€131.96
(€0; €131.96)
kostenhandleiding CVZ
*For SIS model parameters no uncertainty distributions were deﬁned.
†No uncertainty estimate reported; uncertainty range assumed as 90% and 110% of point estimate.
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probability of 0.956 that the bacteria are eradicated at the end
of the month.
Initial resistance (which equals 1 minus the fraction of sensi-
tive strains) was based on the distribution of pathogens among
patients with IAI as in the RCT by Solomkin et al. [9]; the most
frequent isolates were E. coli (about 70%), Bacteroides fragilis
(35%), other Bacteroides spp (73% in ertapenem group and
82% in piperacillin/tazobactam group), and Clostridium spp
(33%). Initial resistance (1 - wt=0) with ertapenem was calculated
as 0.064: Solomkin et al. showed 92.1% biological and clinical
response [9]. This percentage is the combination of clearance
under antibiotic treatment and the fraction of hosts with sensitive
strains. Hence, susceptibility is calculated by dividing 0.921 with
the 0.984 probability that the bacteria are eradicated at the end
of the month (see above). Initial resistance with piperacillin/
tazobactam was calculated as 0.106: Solomkin et al. showed
88% biological and clinical response [9]. Hence, susceptibility is
calculated by dividing 0.88 with the 0.984 probability. The
analyses included pathogens intrinsically resistant to ertapenam
such as enterococci and pseudomonas aeruginosa, and those with
intrinsic or acquired resistance to piperacillin/tazobactam.
Since E. coli is in community-acquired IAI, the most common
EBSL-producing pathogen, an alternative analysis was per-
formed using AMR data for E. coli in community IAI as obtained
from SMART [18]. Worldwide the sensitivity of E. coli to
piperacillin/tazobactam was 0.969 for community-acquired
infections and 0.944 for community and hospital infections com-
bined (2004 data on ﬁle), hence a difference of 0.025. In Europe
the sensitivity of E. coli to piperacillin/tazobactam was reported
to be 0.953 for community and hospital infections combined.
When assuming this 0.025 difference also applicable to Europe
we obtain an estimate of 0.978 for piperacillin/tazobactam for
community-acquired IAI, or an initial resistance of 0.022. For
ertapenem there is similar sensitivity for community and hospital
acquired infections. Hence, we assumed the reported sensitivity
of E. coli to ertapenem of 0.997 also valid for community-
acquired IAI; i.e., an initial resistance of 0.003.
Efﬁcacy, life expectancy, and resource use and cost data. Table 1
also lists the input data for the decision tree. Efﬁcacy of ertapenem
and piperacillin/tazobactam were extracted from the RCT by
Solomkin et al. [9]. In themodel these efﬁcacy estimates were used
for the initial analysis of the cost-effectiveness. Over time the
efﬁcacy estimates will decrease as a function of AMR. When
ertapenem or piperacillin/tazobactam was not efﬁcacious accord-
ing to the trial deﬁnitions of clinical response, patients were
treatedwith another (second line) antibiotic treatment: imipenem/
cilastatin. The efﬁcacy of imipenem/cilastatin was obtained from
Dietrich et al. and assumed constant over time [26]. This study
also provided information to assume amortality of 5%.Mortality
was based on second-line failure and therefore, the mortality was
divided by the probability of failure of second-line treatment.
Given the average age of 45 years of the patients studied by
Solomkin et al. [9], a life-expectancy of 35 years can be expected
when a patient does not die because of the IAI (Centraal Bureau
Voor de Statistiek [CBS] statline). Given the average age of the
population we did not assume a disutility value for the life years
expected when a patient survived an episode of IAI. As a result
the discounted life years are the same as the discounted quality
adjusted life years, i.e., 27.5 QALYs.
Based on Solomkin et al. [9] the average treatment duration
with ertapenem (1 g per day) was 7.6 days and with piperacillin/
tazobactam (9 g per day) 7.8 days. (In the trial therapy was given
for a minimum of 4 full days, unless treatment failure was
identiﬁed earlier, and the suggested maximum duration was 14
full days.) This is in line with guidelines for IAI. [1] Based on
Krobot et al. failure patients were assumed to be treated for 8
days with imipenem/cilastatin (3 g) [27]. With successful treat-
ment with ertapenem or piperacillin/tazobactam, the average
length of hospital stay was 12 days, and without success, i.e.,
need for second line treatment, 22 days [28]. Costs for the
surgical intervention were based on the DRG system for The
Netherlands (DBC) and it was assumed that all patients had two
outpatient visits. All costs were (inﬂated to) 2006 costs.
Analysis
Three series of analyses were performed: 1) a base case scenario
with resistance data extracted from Solomkin et al. [9]; 2) an
alternative scenario based on E. coli resistance data from
SMART and similar initial efﬁcacy; and 3) and a scenario with a
similar initial resistance for piperacillin/tazobactam as for ertap-
enem, but different initial efﬁcacy.
Expected costs and QALYs with ertapenem were compared
with those expected for piperacillin/tazobactam at different
points in time. We made the assumption that all IAI patients over
a period of 60 months used either only ertapenem or only
piperacillin/tazobactam. Results were presented for 5 points in
time, (month 1, 15, 30, 45, and 60). Initial analysis (i.e., month
1) was performed using efﬁcacy data as reported by Solomkin
et al. [9]. For the following months, reduced efﬁcacy data were
obtained from the SIS model. In the analysis a discount rate of
4% was used for costs and 1.5% for QALYs.
The source data are characterized by uncertainty. To incor-
porate uncertainty in the evaluation, a probabilistic sensitivity
analysis (PSA) was performed to quantify the uncertainty in
model outcomes for each scenario of the SIS model. A random
value was repeatedly sampled from distributions reﬂecting the
uncertainty level of the input source data, plugged into the
model, and then the outcome of the model was calculated. For
initial efﬁcacy of ﬁrst line treatment and mortality, beta distribu-
tions were used. For dose and treatment duration, length of
hospital stay, and other medical resource use costs triangular
distributions were used given the lack of data in the literature.
Each outcome was presented with a point estimate along with
uncertainty reﬂected by the 2.5th and 97.5th percentile of the
uncertainty distribution. Acceptability curves were created to
estimate the probability that ertapenem would be cost-effective in
comparison to piperacillin/tazobactam for different willingness-
to-pay ratios, deﬁned as the assumed maximum amount a deci-
sion maker would be willing to pay for a unit of beneﬁt (QALY).
Results
Antibiotic Resistance, Sensitivity and Efﬁcacy over Time
Under the base-case scenario, the initial resistance of ertapenem
and piperacillin/tazobactam was 0.064 and 0.106 and it is
expected that, over time, the resistance will increase with a
slightly greater rate with piperacillin/tazobactam. In Figure 3,
the corresponding sensitivity of bacterial strains to ertapenem
and piperacillin/tazobactam is presented as well as the related
expected efﬁcacy. Initial efﬁcacy of 0.867 with ertapenem and
0.812 with piperacillin/tazobactam is expected to change to
0.680 and 0.558after 5 years when all patients are prescribed
with the same antibiotic.
Under the alternative scenario based on European SMART
data, the initial resistance of ertapenem and piperacillin/
tazobactam was 0.003 and 0.022 and is expected to increase only
slightly over time (See Figure 4). Given the smaller difference in
resistance, it is also expected that the difference in efﬁcacy
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between the two treatments will be smaller: 0.867 for ertapenem
at baseline and 0.856 at 5 years of follow-up, and for
piperacillin/tazobactam 0.867 at baseline and 0.793 at 5 years of
follow-up. In Figure 5, results of the scenario are presented
where ertapenem and piperacillin/tazobactam have the same
initial resistance, 0.064, which increases to 0.266 at 5 years of
follow-up, but different initial efﬁcacy. The efﬁcacy reduces over
time from 0.867 at baseline to 0.680 at 5 years for ertapenem,
and reduces from 0.850 at baseline to 0.667 at 5 years for
piperacillin/tazobactam.
Quality Adjusted Life Years, Costs and Cost-Effectiveness
In Table 2, the expected QALYs, drug costs and total treatment
costs are presented by treatment arm under the base-case
scenario. Over time the expected QALYs will decrease and costs
will increase for both treatments, although at a greater rate for
piperacillin/tazobactam. In Table 3, the difference in costs and
QALYs are presented. The model suggested overall savings of
€355 (95% uncertainty interval €-480; €1205) per patient
when IAI are treated with ertapenem instead of piperacillin/
tazobactam. After 5 years, the cost-savings with ertapenem are
expected to increase to €672 (€-232; €1617), and ertapenem will
additionally result in greater QALYs (0.17; 0.07–0.30). The
probability of the incremental cost per QALY gained being
within a threshold for cost-effectiveness (€20,000) was initially
94% and increased to >99% at 5 years (Figure 6).
In Table 4, the difference in costs and QALYs are presented
when the development of resistance is estimated according to the
SMART data, and similar initial efﬁcacy. Overall savings of €94
(€-760; €893) per patient when IAI are treated with ertapenem
instead of piperacillin/tazobactam are expected. After 5 years,
the cost-savings with ertapenem are expected to increase to €395
(€-454; €1186), and ertapenem will result in 0.09 (0.01; 0.21)
additionally QALYs. Under a scenario with similar initial resis-
tance, the costs difference favoring ertapenem will slightly
decrease because of discounting, and the difference in QALYs,
slightly favoring ertapenem as well, will remain constant over 5
years (See Table 5).
Discussion
The current evaluation showed that ertapenem, relative to
piperacillin/tazobactam, is a cost saving and possibly an eco-
nomically dominant treatment for community-acquired compli-
cated IAI in The Netherlands. The prescription of antibiotic
treatment is associated with AMR. With the current study,
we illustrated how development of AMR can be incor-
porated in a cost-effectiveness evaluation of antimicrobial
therapy. If the AMR of ertapenem and piperacillin/tazobactam
as extracted from the ertapenem trial [9] is considered appli-
cable to The Netherlands, it is expected that the AMR of
piperacillin/tazobactam will develop at a greater rate than the
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Figure 3 Development of resistance and efﬁcacy
of ertapenem and piperacillin/tazobactam over
time for the treatment of abdominal infections,
base-case scenario.
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Figure 4 Development of resistance and efﬁcacy
of ertapenem and piperacillin/tazobactam based on
E. coli resistance data from SMART.
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AMR with ertapenem. As a result, cost savings and QALY
gains with ertapenem will increase over time. If the AMR for
ertapenem and piperacillin/tazobactam in The Netherlands is
more in line with the European data of the SMART study (i.e.,
smaller absolute AMR and a smaller difference) the develop-
ment of AMR over time for both treatments will be at a much
smaller rate and the difference in costs and QALYs between
ertapenem and piperacillin/tazobactam will be smaller, still
favoring ertapenem though. If there is no difference in the
AMR of ertapenem and piperacillin/tazobactam, the develop-
ment of AMR over time is the same for both interventions.
As a result, the absolute responses are decreasing, but the
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Figure 5 Development of resistance and efﬁcacy
when piperacillin/tazobactam has the same initial
resistance as ertapenem.
Table 2 Outcomes of model for complicated intraabdominal infections
Ertapenem Piperacillin/tazobactam
Mean
95% uncertainty interval
Mean
95% uncertainty interval
Low High Low High
Month 1
QALYs 27.30 27.16 27.40 27.23 27.04 27.36
Drug cost €511 €477 €627 €660 €614 €807
Total cost €9,564 €8,665 €14,553 €9,919 €9,087 €15,156
Month 15
QALYs 27.27 27.12 27.38 27.17 26.95 27.33
Drug cost €537 €503 €661 €698 €653 €863
Total cost €9,688 €8,799 €14,693 €10,107 €9,272 €15,346
Month 30
QALYs 27.22 27.03 27.35 27.10 26.84 27.29
Drug cost €575 €542 €716 €754 €708 €942
Total cost €9,873 €9,008 €14,916 €10,374 €9,564 €15,620
Month 45
QALYs 27.14 26.92 27.31 27.00 26.68 27.24
Drug cost €627 €593 €795 €824 €778 €1050
Total cost €10,124 €9,289 €15,163 €10,716 €9,902 €15,962
Month 60
QALYs 27.05 26.76 27.26 26.88 26.50 27.17
Drug cost €694 €661 €897 €908 €863 €1,181
Total cost €10,451 €9,628 €15,510 €11,123 €10,297 €16,312
QALYs, quality-adjusted life years.
Table 3 Cost-effectiveness of ertapenem versus piperacillin/tazobactam over time, base-case scenario
Incremental cost (in euros) Incremental effectiveness (QALYs)
Mean
95% uncertainty interval
Mean
95% uncertainty interval
Low High Low High
Month 1 -€355.32 -€1204.74 €479.65 0.08 -0.02 0.20
Month 15 -€419.11 -€1269.72 €413.43 0.09 0.00 0.22
Month 30 -€501.59 -€1353.01 €332.28 0.12 0.02 0.25
Month 45 -€591.14 -€1469.48 €278.63 0.14 0.05 0.28
Month 60 -€672.21 -€1617.17 €231.94 0.17 0.07 0.30
QALYs, quality-adjusted life years.
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difference in efﬁcacy as shown by Solomkin et al. remains con-
stant over time [9].
Transmission SIS models have been used to evaluate the
impact of prophylaxis and treatment of nosocomial bacterial
infections on the development of AMR. Given the objective of
the study to evaluate the cost-effectiveness of treatment of
community-acquired IAI, and the notion that AMR is increasing
in the community, we opted to also use a compartment model to
capture the development of AMR in this community-acquired
infection and to evaluate its impact on the cost-effectiveness. One
can argue that an important epidemiological difference between
hospital-acquired infections and community-acquired infections
is that a hospital has highly dynamic populations, unlike com-
munities in which resistance is studied [22]. Nevertheless, it has
been shown that population density does have a relation with the
prevalence of AMR [23]. Similar to the hospital environment,
living in close contact with other persons harboring resistant
pathogens is a risk factor for AMR in the community [23].
Hence, the use of a transmission model for AMR in the commu-
nity can in our opinion be defended. Of course, these transmis-
sion models do not aim to provide a precise reﬂection of these
processes in real communities, but rather, in a quantitative
manner can help evaluate the consequences of antibiotic pre-
scription over time, e.g., development of resistance in a nonlinear
fashion, and the greater the AMR the greater the rate of future
development with antibiotic use.
To develop a model for the treatment of IAI taking into
account development of AMR, several simpliﬁcations and
assumptions were made with respect to actual routine practice.
First, with the SIS model, the increase in AMR was primarily a
function of the (initial) fraction of the population infected with
resistant strains out of the total infected population, and the
difference in recovery rate between resistant strains and sensitive
strains. Nevertheless, in bowel colonization studies, the fre-
quency of colonization with resistant enterobacteriaceae substan-
tially increased in patients treated with piperacillin/tazobactam
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Figure 6 Cost-effectiveness acceptability curves
reﬂecting probability of cost-effectiveness of ertap-
enem versus piperacillin/tazobactam by willingness-
to-pay level.
Table 4 Cost-effectiveness of ertapenem versus piperacillin/tazobactam over time, alternative scenario with resistance data from the Study for
Monitoring Antimicrobial Resistance Trends program
Incremental cost (in euros)
Incremental effectiveness
(quality-adjusted life years)
Mean 95% uncertainty interval Mean 95% uncertainty interval
Month 1 -€94.74 -€893.43 €759.96 0.00 -0.09 0.10
Month 15 -€131.91 -€926.37 €727.61 0.01 -0.07 0.11
Month 30 -€190.01 -€986.30 €677.05 0.03 -0.05 0.13
Month 45 -€274.51 -€1075.03 €582.92 0.05 -0.03 0.16
Month 60 -€394.62 -€1186.18 €453.64 0.09 0.01 0.21
Table 5 Cost-effectiveness of ertapenem versus piperacillin/tazobactam over time, alternative scenario with piperacillin/tazobactam having the same
initial resistance as ertapenem in The Netherlands
Incremental cost (in euros)
Incremental effectiveness
(quality-adjusted life years)
Mean 95% uncertainty interval Mean 95% uncertainty interval
Month 1 -€174.56 -€1158.11 €697.21 0.02 -0.11 0.19
Month 15 -€171.50 -€1123.65 €690.38 0.02 -0.11 0.18
Month 30 -€167.01 -€1099.37 €702.71 0.02 -0.10 0.17
Month 45 -€161.05 -€1098.59 €703.29 0.02 -0.09 0.16
Month 60 -€153.55 -€1072.95 €722.72 0.02 -0.09 0.15
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but not in patients treated with ertapenem. Hence, the SIS model
does not capture the difference in resistance proﬁle between
ertapenem and piperacillin/tazobactam, which probably has
resulted in an underestimation of the cost and QALY advantages
observed with ertapenem over time.
Second, prescription of imipenem/cilastatin as a second
line antibiotic treatment after an ertapenem or piperacillin/
tazobactam failure did not inﬂuence AMR for imipenem/
cilastatin, and therefore the efﬁcacy of imipenem/cilastatin
remained constant over time. A third simpliﬁcation compared to
routine practice is the assumption that all patients with IAI are
treated with piperacillin/tazobactam or all patients are treated
with ertapenem. Since, the frequency of prescription inﬂuences
the development of AMR, these 100% “prescription-of-one-
antibiotic-for-all-IAI” scenarios most likely have resulted in an
overestimation of the development of AMR for both ertapenem
and piperacillin/tazobactam. As outlined above, the prescription
of another antibiotic for the population of patients with IAI—e.g.,
ceftriaxone/metronidazole—decreases the rate of development for
ertapenem and piperacillin/tazobactam. On the other hand, resis-
tance to ceftriaxone is co-linked to resistance to piperacillin/
tazobactam but not to resistance to ertapenem [19], thereby
increasing AMR at a greater rate with piperacillin/tazobactam
then what is expected based on the prescription of piperacillin/
tazobactam.
We opted for a decision tree to reﬂect the economic conse-
quences of IAI treatment. Alternatively, a Markov structure with
different health states seems an interesting alternative. Such a
structure probably enables a more realistic approach to the
course of treatment and outcomes. For example, Edwards et al.
used such an approach for a cost-utility analysis comparing
meropenem with imipenem plus cilastatin in the treatment of
severe infections in intensive care [29]. The disadvantage of a
Markov model, however, is the methodological challenge in
linking such a model with the SIS compartment model, thereby
possibly limiting the transparency of the overall modeling work.
In addition to using a decision tree, some other model struc-
ture related simpliﬁcations were made. First, the assumption of a
utility value of 1 for the expected life years when a patient
survived an IAI can be argued to be optimistic, and the average
utility for the remaining life expectancy might possibly be some-
what lower, e.g., 0.9. Nevertheless, a utility value of 0.9, by
which the QALY estimates will be reduced by 10%, would still
have resulted in economically dominant ﬁndings. Second, no
difference in the life expectancy was assumed for a patient that
was successfully treated and a patient that has sequelae. Since,
the probability of sequelae was lower for ertapenem relative to
piperacillin/tazobactam (respectively 1.6% and 2.3% at month
1, and 3.9% and 5.4% at month 60) this simpliﬁcation has
resulted in an underestimation of the life years gained with
ertapenem relative to piperacillin/tazobactam, if there is a differ-
ence in life expectancy between patients with and without
sequelae. On the other hand, we did not differentiate the average
utility between these types of patients, which could have resulted
in some overestimation of the average utility for both treatments,
thereby overestimating the average utility gained with ertap-
enem. Nevertheless, in combination, the assumption of a similar
life expectancy and utility for patients with and without sequelae
did most likely not bias the estimate of the QALYs gained with
ertapenem relative to piperacillin/tazobactam. A third simpliﬁ-
cation was that adverse events were not taken into consideration,
and the impact on treatment switches. This decision was driven
by the similar proportion of adverse events seen with ertapenem
and piperacillin/tazobactam and the adverse events that occurred
were mild and not associated with extensive costs [9].
Apart from choices regarding the model structure, input data
are another source of uncertainty, either because of sampling
error or simply because of lack of data thereby making assump-
tions or relying on expert opinion. With the large number of
input data, quantifying the uncertainty associated with the cost-
effectiveness estimates is essential for the validity of the models.
Although single and multiway sensitivity analysis may be used
to investigate the effect of different model parameters, only PSA
allows for the interaction of different sources of uncertainty
present within a model. In the current evaluation we only deﬁned
uncertainty distributions for the parameters of the decision tree.
With multiple scenarios the impact of changes in the rate of
development of AMR was evaluated. Although this helps under-
standing the impact of the development of AMR over time, the
overall uncertainty in the cost-effectiveness estimates beyond the
ﬁrst month of treatment is underestimated. For future analysis, it
suggested to deﬁne uncertainty distributions for both parameters
of the SIS compartment model as well as the decision tree, and to
evaluate these simultaneously.
A drawback of the current evaluation is that only one trial
was used as a source for efﬁcacy estimates for ertapenem and
piperacillin/tazobactam [9]. Recently two similar, but smaller,
trials were published [30,31]. Hence, combining the results of the
three available studies by means of meta-analysis, and using the
obtained pooled estimates for the cost-effectiveness analysis is of
interest and will improve the analysis. Nevertheless, we do not
expect that these pooled results will result in different conclu-
sions. First, despite the absence of signiﬁcant differences favoring
ertapenem in these trials, a pooled estimate will still reﬂect a
relative efﬁcacy estimate (numerically) favoring ertapenem
because of the larger sample size of the Solomkin trial [9].
Second, in our alternative scenario analysis, we used smaller
differences in efﬁcacy than those reported by Solomkin et al., and
this still resulted in economic outcomes favoring ertapenem.
Model parameter f is an important factor for the development
of AMR, and therefore for changes in cost-effectiveness over
time. In the presented analyses the costs and beneﬁts of the two
treatments were compared at different points in time by assuming
situations where all patients were treated with either piperacillin/
tazobactam or ertapenem. In other words two strategies were
compared with either 100% ertapenem, or 100% piperacillin/
tazobactam over time. Based on this assumption, it is likely that
if all patients were treated with ertapenem, the resistance to
piperacillin/tazobactam will not increase any further, in contrast
to ertapenem. At a certain point the sensitivity of bacteria to
ertapenem will become lower than for piperacillin/tazobactam,
as illustrated in Figure 5. From an AMR point of view it seems
preferable to prescribe both antibiotics (50% ertapenem and
50% piperacillin/tazobactam) to the patient population of inter-
est from that point onwards. As a result of this “50/50 prescrip-
tion,” AMR continues to develop less rapidly than when only
one antibiotic is prescribed in the population (See Figure 7). As a
result, the effectiveness over time of the combined strategy will
remain greater than of piperacillin/tazobactam or ertapenem
alone. When such a strategy is compared with a strategy of only
piperacillin/tazobactam the cost-savings are €482 at 30 months
combined with 0.13 QALY savings. At 60 months, the cost-
savings are €1003 and 0.28 QALYs savings. At 30 months the
50/50 prescription strategy is €20 more expensive than the ertap-
enem only strategy and results in similar QALYs. At 60 months,
€330 will be saved combined with 0.11 QALYs saved. Overall,
these ﬁndings imply that both from a cost-effectiveness point of
view as well as a resistance point of view it seems reasonable to
recommend using ertapenem as an alternative to piperacillin/
tazobactam, until comparable resistance shows. From that point
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onwards a 50/50 strategy is preferred. To develop this notion
further, interesting questions from a policy perspective that in
principle can be answered with the approach illustrated in this
article are for example: “What is the optimal initial market share
of use of ertapenem that would yield the lowest growth in
resistance (as per equation 7)?” or “What about combining
ertapenem with other antibiotics, such as those that may offer
complementary coverage for microbes not covered by ertapenem,
such as pseudomonas, which incidentally, is also of some impor-
tance in IAI?” Although the modeling work here may be sufﬁ-
cient to discern some overall trends, caution has to be made to
make speciﬁc policy recommendations. Many treatment options
are relevant for community-acquired IAI [1]. Recommended
regimens for patients with more severe infections include mero-
penem, imipenem/cilastatin, third- or fourth-generation cepha-
losporins plus metronidazole, ciproﬂoxacin plus metronidazole,
and piperacillin/tazobactam. For the current study we focused on
this latter treatment given the availability of head-to-head data
for efﬁcacy. For future analysis, it is of interest to elaborate on the
analyses by including a range of different interventions based on
indirect comparisons, and to evaluate what is the most cost-
effective prescription strategy over time considering differences in
AMR.
In conclusion, given the underlying assumptions and data
used, this economic evaluation demonstrates that ertapenem is a
cost-saving and possibly an economically dominant therapy over
piperacillin/tazobactam for the treatment of community-
acquired complicated IAI in The Netherlands. Although the
prevalence of ESBL producing organism is expected to be rela-
tively low in community-acquired infections in The Netherlands,
any difference in AMR between ertapenem and piperacillin/
tazobactam will result in increasing cost and outcome differences
over time favoring ertapenem. Accounting for development of
AMR as a function of prescription in cost-effectiveness evalua-
tions can help answer interesting questions from a policymaking
point of view. Research to overcome some methodological chal-
lenges is desirable.
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